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 Abstract 
Colorectal cancer (CRC) is one of the most common cancers with a high rate of 
morbidity and mortality worldwide. The incidence of CRC is similar in men and women 
but is distributed uniformly globally. It has been demonstrated that epigenetic alterations 
which may cause changes in the expression of microRNA, DNA methylation and 
histone acetylation that results in inheritable modifications in gene expression in 
colorectal epithelial cells, plays a crucial role in the development of CRC. Recently, 
targeting epigenetic modification has emerged as a potentially important treatment 
approach in CRC. The US Food and Drug Association has approved the use of some 
epigenetic drugs that may be able to inhibit or reverse these alterations and also 
enhance sensitivity to chemotherapeutic agents and radiotherapy in CRC. In this review 
we have summarized the recent pre-clinical and clinical trial studies investigating the 
therapeutic value of using epigenetic drugs as novel therapeutic approach in CRC 
treatment. 
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Introduction 
Colorectal cancer (CRC) is one of the most common cancers with a high rate of 
morbidity and mortality globally [1]. More than one million cases of CRC are diagnosed 
annually mainly in developed countries [2, 3]. Both men and women have a similar 
incidence rate for CRC[4]. The five-year survival rate is dependent on the stage at 
diagnosis, being approximately 90% in early stages of disease, and less than 10% in 
distant metastatic stage [2]. The incidence rate of CRC varies globally [5]. Some 
European countries, Australia, United States, Canada, New Zealand and Oceania are 
high rate regions. In contrast, in some countries of Africa, East and central Asia and 
parts of South America this rate is low [3, 5]. In addition to age, several risk factors are 
considered to be important for CRC: these include obesity, smoking, diabetes, high 
consumption of red meat and alcohol, inflammatory bowel disease, positive family 
history and some specific genetic factors[6]. There has been an increased use of 
colonoscopy, early detection and treatment, the CRC-related mortality has started to fall 
in high-income countries but the incidence rate has continued to increase in low-income 
countries [3]. It has been demonstrated that genetic and epigenetic alteration in 
colorectal mucosa cells can lead to neoplastic change [2]. 
Epigenetic change is an intracellular process that results in modifications of gene 
expression with no association of changes in DNA sequences [7]. Epigenetic alteration 
that consists of changes in the expression of microRNA (miRNA or miR), DNA 
methylation and histone acetylation play a crucial role in carcinogenesis from its 
initiation to subsequent metastasis [8]. In contrast to genetic changes, several 
epigenetic alterations can be reversed by treatment with particular category of drugs 
that are termed epigenetic drugs and restore genes to their original expression and 
function [9]. Although there are several epigenetic drugs, few of them are approved by 
US Food and Drug Association (FDA). Overall, epigenetic drugs are categorized into 
two separate group: 1) Drugs that inhibit DNA methylation, and 2) Drugs that inhibit 
histone deacetylation. In the past decade, there has been some progress in 
understanding of how epigenetic alterations affect tumors pathogenesis. In addition to 
inhibiting cancer development, there is some evidence that treatment with epigenetic 
drugs can enhance chemo- and radio-sensitivity [8]. Recently, targeting epigenetic 
modification has been emerged as a potential approach to treatment in CRC and may 
represent a new ideas of personalized medicine. The purpose of this current study was 
to summarize the main results of studies used various epigenetic drugs for controlling 
cancer progression and treatment of CRC. 
 
 
Molecular pathogenesis of colorectal cancer 
Our understanding of the molecular aspect of CRC is evolving as new molecular 
detecting techniques have emerged. Epigenetic changes are becoming an important 
part of the pathogenesis CRC. Tens of thousands of mutations are reported in colon 
cancer cells and only a few of these are considered to be important driver or passenger 
mutations [10]. These mutations lead to genomic or epigenomic instability. 
Chromosomal instability (CIN), microsatellite instability (MSI) and aberrant methylation 
pattern are the 3 main genomic and epigenomic instabilities. These categories overlap 
with each other and according to recent advances in molecular analysis of CRC, it is not 
possible to distinguish these categories as independent and unique cause for CRC 
progression. During CIN, the most common form of genetic instability in CRC, numerical 
chromosomal changes and structural aberrations are common findings [11]. Impairment 
in double stranded DNA repair mechanisms as well as deregulation of mitotic spindle, 
centromere and telomere dysfunction are major causes of CIN. Microsatellite instability 
(MSI) which is another common finding in CRC, is seen in approximately 15% of 
tumors. These tumors will mostly represent near normal karyotype and in some cases is 
accompanied by CIN [12]. It has been considered that dysfunction of DNA mismatch 
repair system is the main cause of MSI in CRC. Aberrant methylation or mutations of 
mismatch repair genes such as MLH1 is seen in MSI cancers [13]. CpG island 
methylator phenotype (CIMP) is the third cause of CRC pathogenesis, which 
demonstrates a global hypomethylation and also hypermethylation of CpG islands [14]. 
The defect in CIMP positive colorectal tumors may result in hypermethylation of the 
MMR genes promoters and therefore silencing of these repair genes [15].  
 
Important enzymes involved in the epigenetic alterations of CRC 
Some mechanisms are considered to be the most important epigenetic changes 
in CRC. CpG-island methylation is an important epigenetic alteration. The human 
genome has many CpG dinucleotide sites which are called CpG islands when become 
repeated in a specific sequence of DNA. CpG island are reffered to to those part of 
genome containing G or C content greater than 50%, with approximate equal number of 
CpG and GpC [16]. CpG island methylation refers to the methylation of cytosine 
nucleotides. This methylation process is catalysed by DNA methyltransferase (DNMT). 
There are 3 types of DNMT enzymes. DNMT1 is responsible for maintenance of DNA 
methylation pattern during cell proliferation. This enzyme copies the CpG methylation 
pattern from parental DNA to daughter’s DNA during S phase [17]. DNMT1 is also 
responsible for imprinting, tumorigenesis and embryogenesis [18]. It has also be shown 
that DNMT1 function is essential for progenitor cell function. Depletion of this enzyme 
will result in premature cell differentiation and tissue loss [19]. Recently the function of 
DNMT enzyme has emerged as being important in the determination of cancer 
prognosis and individualized treatment. As an example, cervical cancer cells express 
higher levels of DNMT1 in contrast to normal tissue and this is strongly associated with 
poor survival [20]. Another example for DNMT1 response to therapy is in CRC. It has 
been shown that DNMT1 disruption is associated with resistance to DNMT inhibitors 
[21]. Deregulation of DNMT1 activity is considered as an oncogenic phenomenon. 
Mutations in enzyme domains as well as activation or inactivation of alternative 
mechanisms targeting DNMT1 is responsible for epigenetic changes in cancer cells. 
Hyper activated signaling pathways such as PI3/PKB and Ras-AP1 as well as loss of 
inhibition of Rb and P53 pathways on DNMT1 are important mechanisms for promoting 
cancers [22]. DNMT3 is another family of DNMT enzymes, consisting of DNMT3a and 
DNMT3b and an inactive regulator, DNMT3L [23]. DNMT3a and DNMT3b cause DNA 
methylation, de novo, during germ cell differentiation [24]. Recently, it has been shown 
that the maintenance of methylation is not only provided by DNMT1; DNMT3 is an 
essential factor [23]. Regardless of methylation capacities, DNMT1 and both DNMT3a 
and DNMT3b can repress transcription partially through activation of histone 
deacetylase (HDAC). DNMT1 forms a stable complex with transcription factors such as 
HDAC1 and DNMT3 and DNMT3b will interact with HDAC through their ATRX-like PHD 
domain [25]. HDACs are group of enzymes that remove the acetyl group from histones; 
allowing the histones wrap DNA more tightly. Tighter wrapping reduces the accessibility 
of DNA for transcription factors [26]. There are many proteins working together with 
HDACs in order to form a repressive complex. Methyl groups at CpG islands are the 
initiators of recruitment of HDAC complex [26]. Another mechanism is that HDAC, 
regulates the acetylation of important proteins such as P53, Sp3 and E2F. 
Deacetylation of DNA sequence specific transcription factors are also linked to reduced 
DNA transcriptional activity or binding [27]. The role of HDACs in cancer is still under 
active research and many mechanisms for cancer development are considered to 
involve HDACs. Aberrant recruitment of HDACs is often found in malignancies such as 
acute promyelocytic leukemia. HDACs expression is variable in different cancers. 
Transcriptional repression of tumor suppressor genes is another common mechanism in 
tumor development and progression [28]. Increased expression of HDAC1 is seen in 
colon cancer, breast and gastric cancer while overexpression of HDAC2 is mostly seen 
in cervical and colorectal carcinoma with loss of APC expression [27, 29-31]. Another 
group of enzymes that are important in epigenetic research are the Histone 
acetyltransferases (HATs). These enzymes acetylate histone proteins by transferring 
acetyl group from acetyl-CoA. Generally, histone acetylation is linked to transcriptional 
activation and euchromatin. Histone acetylation neutralizes histone charge, weakens 
histones and therefore reduce chromatin compaction. The acetylated histone can also 
work as a “histone code” which allows recognition sites for factors which are essential 
for gene expression or repression [32]. Aberrant HATs activities may result in several 
cancers, including colon and lung cancers [33]. As for HDACs, genes that encode HATs 
can undergo mutation, translocation and amplifications. Missense mutations and 
truncating mutations in some HATs (p300) have been identified in CRC [34]. The other 
enzyme which is important in epigenetic modifications is histone demethylase. Histone 
lysine demethylase is a chromatin modifier which acts along with DNA methylation. 
Lysine specific demethylase 1 is a well-known example of histone demethylase which 
plays an important role during epidermal mesenchymal transition [35]. Absence of this 
enzyme may result in repression failure of E-cadherin transcription. Overexpression of 
this enzyme is linked to proliferation, invasion and metastasis in different cancers. It has 
been proposed that lysine specific demethylase 1 may stimulate colon cancer 
metastatsis [36]. Another histone modifying enzyme is histone methyltransferase (HMT) 
which catalyze transfer of methyl group to histone protein residues. Inactivation of HMT 
genes such as SETD2 are considered as common event human cancers such as renal 
cell carcinoma [37]. HMT subunits such as SUZ12 and PCL3 over expression is 
reported in colon cancer [38, 39].  
 
Epigenetic drugs in colorectal cancer 
Advances in our understanding of the particular epigenetic alteration in 
conditions such as CRC have resulted in a new class of chemical compounds that have 
been termed epigenetic drugs. Some of these drugs have been used in CRC patients 
and cancer cell lines, as follows: 
 
 
Histone deacetylase inhibitor (HDACi) 
HDACi are a group of drugs that can be purified from natural sources or 
synthesized. Four major groups of this epigenetic drug category are benzamides, 
hydroxamates, cyclic peptides and aliphatic acids. It has been proposed that normal 
cells are resistant and tumor cells are sensitive to HDACi and undergo growth arrest or 
cell death. Upregulation of p21 and blocking cyclin/CDK complexes are mostly the 
cause of inhibited cell cycle arrest and difrentiation by HDACi [40]. This drug category 
includes: suberoylanilide hydroxamic (vorinostat), panobinostat, resveratrol, 
carbamazepine, arginine butyrate, sodium butyrate, plitidepsin, valproic acid, entinostat, 
romidepsin, droxinostat, resminostat, belinostat and SB939. Liu et al. evaluated the 
anticancer activity of Largazole in vivo and in vitro. They studied its effects in several 
colon cancer cell lines and reported that this HDACi drug is active against several colon 
cancer cells. They also demonstrated that largazole inhibits HDAC in mouse with 
xenograft tumor tissue and tumor cell apoptosis and growth inhibition was prominent 
[41]. Munster et al. evaluated the effect of supra-therapeutic doses of vorinostat, on QTc 
interval in patients with advanced cancers including CRC. Electrocardiographic holter 
monitoring before administration and till 24 h after that revealed that administration of 
800 mg vorinostat is not correlated with prolongation of the QTc interval [42]. Wilson et 
al. conducted the study to evaluate the safety of chemotherapeutic treatment consisted 
of vorinostat and 5-fluorouracil (5-FU) in patients suffered from metastatic CRC who 
previously failed 5-FU-based chemotherapy. This study was terminated because of 
poorly tolerated drugs combination [43]. Maximum tolerated dose (MTD) of vorinostat 
was assessed in combination with FOLFOX regimen that includes fluorouracil (FU), 
folinic acid, also known as leucovorin and oxaliplatin in twenty-one patients with 
refractory CRC. Finally, 300 mg orally twice daily x 1week every 2 weeks was 
determined as a MTD of vorinostat in combination with FOLFOX regimen [44]. 
Vansteenkiste et al. with investigation of patients with refractory or relapsed cancer 
including CRC found that daily oral vorinostat regimen for 14 days/3 weeks is tolerable 
only at 200 mg twice daily, and no clinical responses were observed [45]. Hamberg et 
al. evaluated the feasibility of co-administration of panobinostat with ketoconazole as a 
CYP3A4 inhibitor in patients with cancer including CRC and results showed that this co-
administration is feasible [46]. Fakih et al. investigated metastatic CRC patients who 
had chemotherapeutic response failure. Regarding the synergistic effect of combination 
of vorinostat and 5-FU in preclinical models, they administered low dose (800 mg) and 
high dose (1400 mg) of vorinostat combined with 5-FU. Finally results showed no 
clinically relevant activity for this regime [47]. In a study performed by Patel et al. in a 
twenty patients with CRC, was observed that taking 0.5-1 g of resveratrol orally makes 
sufficient dose to provide anti-carcinogenic effects in gastrointestinal tract. In addition, 
these dose of resveratrol resulted in 5% reduction in cancer cells proliferation [48]. 
Delius and colleagues aimed to diminish neurotoxicity of oxaliplatin by means of 
administration of carbamazepine in patients with advanced CRC. Finally they observed 
no clinical effectiveness [49]. Douillard and colleagues who have used high dose of 
arginine butyrate (ArgB) regimen in contribution with Interleukin-2 (18 MIU/m2) in six 
patients with advanced metastatic cancer, reported liver insufficiency and toxicity. They 
also observed that the MTD for ArgB was 3 g/kg/day[50]. In another clinical trial 
investigated the MTD of combination therapy with plitidepsin and bevacizumab in 13 
patients with advanced cancer including CRC revealed that this regimen was well 
tolerated and no unexpected toxicities were observed. In this clinical trial stable disease 
was the best response. They have concluded that 3.8 mg/m2 of plitidepsin and 10 
mg/kg of bevacizumab is tolerated in advanced carcinomas [51].  A regimen consists 
combination therapy of valproic acid with dose of 5.3 mg/kg and 11 mg/kg bevacizumab 
was observed to be safe with stable disease more than 6 months in patients with 
advanced malignancies including CRC [52]. Ree et al. conducted a clinical trial on 16 
patients with gastrointestinal cancer including CRC to evaluate the MTD of vorinostat in 
combination with palliative radiotherapy. Results showed that administration of 300 mg 
vorinostat daily three hours before radiation is safe and well tolerated. As well biological 
activity of vorinostat when administered with pelvic radiotherapy was also confirmed in 
this study [53]. Mahalingam evaluated patients with advanced cancers including CRC 
and found that MTD of hydroxychloroquine and vorinostat was 600 mg and 400 mg 
orally once per day, respectively. Combination of hydroxychloroquine with Vorinostat did 
not significantly affect the pharmacokinetics of Vorinostat. They also observed that most 
of the evaluated patients did not benefit from combination therapy with this regimen 
[54]. Fakih and colleagues aimed to determine the MTD of vorinostat in combination 
with 5-fluorouracil (5-FU) and leucovorin. Results showed that the MTD of vorinostat 
when orally used in this combination therapy is 1700 mg daily × 3 or 600 mg twice a day 
× 3 days every two weeks [55]. Intermittent combination therapy of vorinostat and 
bortezomib was assessed in a study conducted by Deming et al. and was observed that 
the intermittent dosing protocol did not resulted in better tolerance to vorinostat. As well, 
the MTD of vornostat was determined as 300 mg orally twice daily on days 1–4 and 8–
11 and intravenously use of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21 day 
cycle [56]. Ryan et al. conducted a clinical trial study on 31 patients (2 CRC patients) 
with advanced tumors. They have used oral Entinostat as a HDAC inhibitor. They have 
stated that Entinostat half-life was up to 80 hours. Dose limiting toxicities were anorexia, 
fatigue, nausea and vomiting which were happened in 10mg/m2 in the q14- day 
regimen [57]. Whitehead et al. treated their locally advanced and metastatic CRC 
patients with 13mg/m2 epsipeptide intravenous infusion as a histone deacetylase 
inhibitor. Their patients have failed either one or two chemotherapy regimen. Six 
patients had treatment toxicities as thrombocytopenia, electrocardiographic ST-T 
changes, fatigue, nausea and vomiting, weakness, anorexia, fever and weight loss. 
They have showed that epsipeptide at the mentioned dose is ineffective in CRC patients 
with prior chemotherapy [58]. Howells et al. had evaluated the effect of SRT501, 
micronized resveratrol as an HDACi on CRC and hepatic metastasis. Daily dose of 5 g 
for 2 weeks were well tolerated and apoptosis marker were significantly increased in 
hepatic malignant tissue after administration [59]. Razak et al. used SB939 as a 
competitive histone deacetylase inhibitor in patients with advanced solid tumor including 
CRC. They have shown that this drug is well tolerated in advanced tumors and the 
toxicities were included as fatigue, vomiting, diarrhea and anorexia. The recommended 
phase II dose was 60mg on 5 consecutive days each 14 days [60]. 
 
DNA methyltransferase inhibitor (DNMTi) 
DNMTis are a group of drugs that can inhibit DNA methylation activity of DNA 
methylteransferase and cause a reduction in genomic DNA methylation in some 
cancers. This class of epigenetic drugs can induce demethylation of some genes which 
are silenced epigenetically. Several silenced genes in DNA repair, cell cycle and 
apoptosis including P15, P16, tissue inhibitor of metalloproteinase 3 and cyclin-
dependent kinase inhibitor 1C are reported to be reactivated after administration of 
DNMTi [61]. 5-Azacytidine, 5-Aza-2'-deoxycytidine, also called 5-aza-DC or decitabine, 
hydralazine,procainamideand zebularine are included in this drug category. Braiteh et al 
evaluated the effect of administration of subcutaneous 5-Azacytidineas a 
hypomethylating agent for 10 days with therapeutic dose of oral valproic acid as a 
histone deacetylase inhibitor. Fifty five patients (11 patients with CRC) were enrolled 
and neutropenic fever and thrombocytopenia which were dose limiting toxicities 
occurred at a dose of 94 mg/m2 for 5-Azacytidine. The safe dose of 5-Azacytidine was 
reported to be up to 75 mg/m2. Their patients showed significant decrease in global 
DNA methylation and induced histone acetylation [62]. Li et al. evaluated the effect of 5-
Azacytidine on 63 cancer cell lines including CRC. They have documented enrichment 
in immunomodulatory pathways including interferon signaling, cytokines, chemokines, 
antigen presentation and processing. Up regulation of AZA IMmune gene set (AIM) after 
treatment was evident. According to this study, broad immune stimulatory is a result of 
DNA demethylating agent [63]. Cho et al. evaluated the effect of HDAC inhibitor sodium 
butyrate and demethylating agent 5-aza-DC along with radiation in colon and breast 
cancer cell lines survival. Survival was lower in 5-aza-DC or SB than radiation alone in 
CRC cell lines. The lowest survival was observed when combining 5-aza-DC and SB in 
combination with radiation. So, combination of these agents considered as effective 
agents in radio sensitivity in both colon cancer and breast cell lines [8]. 
 
Histone demethylase inhibitor (HDMi) 
There are several inhibitors reported for histone demethylase. Polyamine and substrate 
analogs have been developed to target catalytic domains of histone demethylase. Re-
expression of aberrantly silenced genes in cancer cells are one of the main functions of 
HDMis. Apoptosis has been reported to be induced in some cancers such as Ewing 
sarcoma [64]. Clorgyline, tranylcypromine, pargyline, GSK-J4, JIB-04, bizine, KDM5-
C70 and GSK2879552 are drugs that are in this class. Han et al. used clorgyline as a 
lysine specific demethylase 1 to treat colon cancer lines. They found that the 
therapeutic efficacy of combining this drug with 5-Aza-CdR (5-Aza-2'-deoxycytidine) has 
synergic effects on enriching H3K4me2 and H3K4me1 and therefore reactivating 
aberrantly silenced genes. Many of the reactivated genes were in interferon signaling 
pathways [65]. 
 
Histone methyltransferase inhibitor (HMTi) and histone acetyltransferases 
inhibitor (HATi)  
Histone methylation is important mechanism in many cellular and biological 
processes including cell cycle, development and DNA repair. Methylation of different 
histones may result in the suppression or derepression of different genes. In addition to 
methylation, other histone modifications include acetylation of lysine tail on histone H3. 
The acetylation leads to an open chromatin formation while deacetylation provide 
closed chromatine and inhibited transcription[66]. HMTi class consists of several drugs 
such as GSK343, GSK126, 3-Deazaneplanocin A, CPI360, EI1, UNC0224 and 
UNC0638. Curcumin and C646 are two drugs that act as inhibitors of histone 
acetyltransferases. Until now, there are no pre-clinical and clinical trial studies 
investigating drugs of these two categories in CRC. 
 
Other new epigenetic drugs and strategies for targeting colon cancer 
HDACis and DNMTis as well as HMTis are well known epigenetic drug classes in 
CRC therapy. In contrast to these well-known drugs, there are new drug recently 
developed for cancer therapy.  Bromodomain and extra-terminal motif (BET) are one of 
these newly emerged epigenetic drugs. BET proteins can regular various cellular 
functions and also play an important role in oncogene expression. BET usually deal with 
super enhancers which are a cluster of acetylated histones. These acetylated histones 
control oncogene expression. BET protein will interfere with these acetylated lysines 
and therefore remodel chromatin structure. BET inhibitors will suppress the effect of 
these enhancers and interact with transcriptional activity [67]. BET inhibitors has been 
successfully used in suppression of MAPK signaling in colorectal samples [68]. Also, Hu 
et al. has demonstrated that BRD4 which is one of the BET proteins are highly 
expressed in colorectal cancer tissue samples and reported that CRC proliferation will 
be reduced by inhibiting BRD4 [69]. Interestingly, a recent study by Hogg et al. has 
proposed that BET inhibitors will be more efficient when used in combination. While 
BET inhibitors require an intact and efficient immune system, using BRD4 inhibiters in 
combination with immune modulatory agents will provide better results in cancer 
therapy [70]. Another newly emerged anti-cancer agents are antagomirs. Antagomirs 
are miRNA inhibitors which can bind to a specific miRNA and alter its function. There 
are plenty of miRNAs introduced to have oncogenic activities. miRNA-21 is one of the 
first miRNA studied for its effects on downregulation of tumor suppressor genes in crc. 
Considering such an important effect has made miRNA-21 as a potential target for 
treating CRC. Song et al. has conducted a study to inhibit this miRNA in CRC. They 
have designed an antagomir which was complementary to miRNA-21 sequence. The 
antagomir could usefully inhibit angiogenesis and proliferation [71]. Another method 
which has been used for targeting miRNAs is using small interfering RNA (siRNA). 
These siRNAs will bind to the desired miRNA and lead to its breakdown. Locked nucleic 
acid (LNA) method is another term which is newly used in targeting miRNAs. LNA is a 
modified RNA nucleotide. These modified RNAs have been proven to be safe, stable 
and non-toxic for using as a good antisense based gene silencing approach. Nedaeinia 
et al. has also used LNA anti miR-21 in CRC cell lines and showed the same results as 
Song and colleagues [72]. 
As mentioned earlier, epigenetic drugs can induce different effects in cancerous cells. 
HDACi and DNMTi are both well known for their potential effect on activating the 
silenced genes in CRC. Nowadays, many new treatment strategies have been provided 
different types of cancers which are using different types of epigenetic drugs in 
combination. One of the earliest and successful example of combination therapy was 
provided by Juergens et al. in lung cancer. They have proved that DNA methylation 
inhibitors in combination with histone deacetylator drug. They have stated that low-dose 
azacitidine and entinostat in patients with solid tumors will be well tolerated and provide 
durable responses in such patients [73]. Combination therapy of epigenetic drugs in 
colon cancer is also becoming an area of interest although there is not sufficient data 
about the promising clinical responses yet. One of the latest clinical trials which has 
recently published their results about combination therapy in CRC patients is Azad et al. 
study. They have treated their patients with a demethylating agent (5-azacitidine) and a 
HDACi (entinostat) and reported greater DNA demethylation in those who had PFS 
above median [74]. The combination therapy of epigenetic drugs and immunotherapies 
in colorectal cancer. The tight link of epigenetics and immunogenicity is becoming more 
evident according to recent advances in epigenetic researches. Li et al. study has 
provided valuable evidence about the effect of low dose 5-AC on CRC cell lines and 
provided new information about immune genes which upregulate significantly by 
epigenetic therapy. This drug has also important in upregulating antigen presenting 
pathways [63]. Combination therapy in other CRC models has also proven that adding 
entinostat or azacitidine to two key checkpoint inhibitors, anti-PD-1 and anti-CTLA-4 
inhibitors has significantly decreased tumor growth and metastasis [75]. Despite of 
favorable results in preclinical studies and as same epigenetic drug combination 
studies, epigenetic and immunomodulatory drugs combinations are also seeking further 
clinical investigation.  
 
Conclusion 
Colorectal cancer is a heterogeneous disease with distinct molecular and clinical 
features, which reflects the wide range of prognostic outcomes and treatment 
responses. It is now believed that among thousands of epigenetic alterations, a small 
subgroup of these may be considered as a CRC driver event. DNA methylation profiles 
have been the most widely studied in CRC, which includes a subset of patients with 
distinct molecular and clinical features, providing us with new potential biomarkers for 
diagnostic, prognostic and therapeutic purposes. This development leads to discovery 
of new drugs and has opened a new therapeutic window for colorectal cancer patients. 
Although there are many studies available for some epigenetic drug classes such 
as DNMTis and HDACis, however, other classes such as Histone methyltransferase 
inhibitor (HMTi) and inhibitors of protein binding to methylated or acetylated histones 
are not widely involved in clinical trials. While cancer therapy regimens are becoming 
friendlier with using epigenetic drugs, however, there is still a long road ahead of 
researchers for studying the exact mechanism and safety of these new drug regimens. 
As most of these drugs are using in combination with previously well-known cancer 
drugs, paying close attention to the tolerability and cost effectiveness of these regimens 
needs further researches, further studies are need to validate emerging agents in the 
treatment of CRC patients 
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Figure 1.Pathogenesis of colorectal cancer.  
 
 
 
Figure 2.Epigenetic alteration in colorectal cancer. This figure illustrate the epigenetic alteration 
in human cells. The top figure shows histone modification. In this figure DNA methylation (Green 
dot) and histone tail acetylation (blue dot) has been shown. Histone acetylation has unfolded 
DNA to an open and transcriptionally active structure. The bottom part of this figure shows 
alteration in DNA methylation. The unmethylated CpG islands (Unfilled green dots) can be 
methylated by DNA methyltransferase (Green dots). Some microRNAs can inhibit this process 
and silence gene expression.    
  
